Equities research analysts expect Verastem Inc (NASDAQ:VSTM) to announce earnings per share of ($0.49) for the current quarter, Zacks reports. Two analysts have made estimates for Verastem’s earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.49). Verastem reported earnings per share of ($0.30) in the same quarter last year, which would indicate a negative year-over-year growth rate of 63.3%. The business is expected to announce its next earnings results on Wednesday, August 14th.

On average, analysts expect that Verastem will report full year earnings of ($1.97) per share for the current fiscal year, with EPS estimates ranging from ($1.98) to ($1.95). For the next financial year, analysts forecast that the business will report earnings of ($1.79) per share, with EPS estimates ranging from ($1.87) to ($1.68). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Verastem.

Verastem (NASDAQ:VSTM) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.05). Verastem had a negative net margin of 315.21% and a negative return on equity of 79.68%. The company had revenue of $1.67 million during the quarter, compared to analyst estimates of $2.84 million.

Several research firms have issued reports on VSTM. ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Cantor Fitzgerald began coverage on shares of Verastem in a research note on Wednesday, April 3rd. They issued an “overweight” rating and a $5.00 price objective for the company. B. Riley restated a “buy” rating and issued a $26.00 price objective (up previously from $24.00) on shares of KEMET in a research note on Thursday, May 9th. Zacks Investment Research upgraded shares of Vistra Energy from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Saturday, July 13th. Finally, Raymond James restated a “buy” rating on shares of Canadian Natural Resources in a research note on Friday, May 10th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $7.66.

NASDAQ VSTM traded down $0.16 during trading hours on Friday, hitting $1.43. The company had a trading volume of 1,349,942 shares, compared to its average volume of 1,804,062. The company has a current ratio of 7.57, a quick ratio of 7.56 and a debt-to-equity ratio of 1.42. Verastem has a 1-year low of $1.16 and a 1-year high of $10.35. The stock has a market cap of $105.64 million, a P/E ratio of -1.04 and a beta of 2.98. The firm has a 50 day moving average of $1.46.

Several institutional investors and hedge funds have recently made changes to their positions in VSTM. Stratos Wealth Partners LTD. acquired a new stake in shares of Verastem during the first quarter worth about $30,000. Amalgamated Bank acquired a new stake in Verastem in the fourth quarter valued at about $35,000. Principal Financial Group Inc. acquired a new stake in Verastem in the fourth quarter valued at about $35,000. Commonwealth Equity Services LLC lifted its position in Verastem by 43.2% in the second quarter. Commonwealth Equity Services LLC now owns 26,697 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 8,054 shares during the period. Finally, BNP Paribas Arbitrage SA acquired a new stake in Verastem in the first quarter valued at about $42,000. Institutional investors and hedge funds own 43.82% of the company’s stock.

About Verastem

Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

See Also: How Investors Use a Balance Sheet

Get a free copy of the Zacks research report on Verastem (VSTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.